세프트리악손 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "세프트리악손" in Korean language version.

refsWebsite

Global rank Korean rank

17nih.gov

4^th place

14doi.org

2^nd place

3^rd place

7web.archive.org

1^st place

5semanticscholar.org

11^th place

310^th place

2drugs.com

399^th place

141^st place

2books.google.com

3^rd place

9^th place

2archive.org

6^th place

18^th place

1handle.net

102^nd place

307^th place

1cdc.gov

218^th place

52^nd place

1fda.gov

447^th place

433^rd place

1medscape.com

719^th place

424^th place

1utah.edu

2,446^th place

1,801^st place

archive.org

Shiffman ML, Keith FB, Moore EW (December 1990). “Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility”. 《Gastroenterology》 99 (6): 1772–8. doi:10.1016/0016-5085(90)90486-K. PMID 2227290.
《Red Book: Pharmacy's Fundamental Reference》 114판. PDR Network, LLC. 2010. ISBN 9781563637513.

books.google.com

Fischer J, Ganellin CR (2006). 《Analogue-based Drug Discovery》. John Wiley & Sons. 495쪽. ISBN 9783527607495.
《Nursing Pharmacology Made Incredibly Easy!》. Lippincott Williams & Wilkins. 2012년 3월 7일. 496쪽. ISBN 9781451146240. 2016년 6월 3일에 원본 문서에서 보존된 문서.

cdc.gov

Centers for Disease Control Prevention (CDC) (December 2020). “Guidelines for Gonococcal Infection, 2020.”. 《MMWR. Morbidity and Mortality Weekly Report》 69 (50): 1911–1916. doi:10.15585/mmwr.mm6950a6. PMC 7745960. PMID 33332296.

doi.org

dx.doi.org

Beam TR (1985). “Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life”. 《Pharmacotherapy》 5 (5): 237–53. doi:10.1002/j.1875-9114.1985.tb03423.x. PMID 3906584. S2CID 25559476.
Centers for Disease Control Prevention (CDC) (December 2020). “Guidelines for Gonococcal Infection, 2020.”. 《MMWR. Morbidity and Mortality Weekly Report》 69 (50): 1911–1916. doi:10.15585/mmwr.mm6950a6. PMC 7745960. PMID 33332296.
Shiffman ML, Keith FB, Moore EW (December 1990). “Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility”. 《Gastroenterology》 99 (6): 1772–8. doi:10.1016/0016-5085(90)90486-K. PMID 2227290.
Shrimali JD, Patel HV, Gumber MR, Kute VB, Shah PR, Vanikar AV, Trivedi HL (November 2013). “Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation”. 《Indian Journal of Critical Care Medicine》 17 (6): 394–5. doi:10.4103/0972-5229.123465. PMC 3902580. PMID 24501497.
Guleria VS, Sharma N, Amitabh S, Nair V (Sep–Oct 2013). “Ceftriaxone-induced hemolysis”. 《Indian Journal of Pharmacology》 45 (5): 530–1. doi:10.4103/0253-7613.117758. PMC 3793531. PMID 24130395.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). “Ceftriaxone and acute renal failure in children”. 《Pediatrics》 133 (4): e917–22. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). “Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events”. 《Pediatrics》 123 (4): e609–13. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923.
van Heijenoort J (March 2001). “Formation of the glycan chains in the synthesis of bacterial peptidoglycan”. 《Glycobiology》 11 (3): 25R–36R. doi:10.1093/glycob/11.3.25r. PMID 11320055. S2CID 46066256.
Scheffers DJ, Pinho MG (December 2005). “Bacterial cell wall synthesis: new insights from localization studies”. 《Microbiology and Molecular Biology Reviews》 69 (4): 585–607. doi:10.1128/MMBR.69.4.585-607.2005. PMC 1306805. PMID 16339737.
Nau R, Sörgel F, Eiffert H (October 2010). “Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections”. 《Clinical Microbiology Reviews》 23 (4): 858–83. doi:10.1128/CMR.00007-10. PMC 2952976. PMID 20930076.
Arvidsson A, Alván G, Angelin B, Borgå O, Nord CE (September 1982). “Ceftriaxone: renal and biliary excretion and effect on the colon microflora”. 《J Antimicrob Chemother》 10 (3): 207–15. doi:10.1093/jac/10.3.207. PMID 6292158.
Blumer J (September 1991). “Pharmacokinetics of ceftriaxone”. 《Hosp Pract (Off Ed)》. 26 Suppl 5: 7–13; discussion 52–4. doi:10.1080/21548331.1991.11707737. PMID 1918224.
Balant L, Dayer P, Auckenthaler R (1985년 4월 1일). “Clinical pharmacokinetics of the third generation cephalosporins”. 《Clinical Pharmacokinetics》 10 (2): 101–43. doi:10.2165/00003088-198510020-00001. PMID 3888488. S2CID 23478077.
Klein NC, Cunha BA (July 1995). “Third-generation cephalosporins”. 《Med Clin North Am》 79 (4): 705–19. doi:10.1016/s0025-7125(16)30034-7. PMID 7791418.

drugs.com

“Ceftriaxone (Rocephin) Use During Pregnancy”. 《Drugs.com》. 2019년 12월 12일. 2019년 12월 24일에 확인함.
“Ceftriaxone Sodium Monograph for Professionals”. Drugs.com. 2016년 5월 31일에 원본 문서에서 보존된 문서. 2016년 8월 27일에 확인함.

fda.gov

accessdata.fda.gov

“Rocephin Prescribing Information” (PDF). Roche. 2016년 3월 4일에 원본 문서 (PDF)에서 보존된 문서. 2015년 11월 1일에 확인함.

handle.net

hdl.handle.net

World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

medscape.com

“The Use of Cephalosporins in Penicillin-allergic Patients”. 《www.medscape.com》. 2015년 11월 14일에 원본 문서에서 보존된 문서. 2015년 11월 10일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Beam TR (1985). “Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life”. 《Pharmacotherapy》 5 (5): 237–53. doi:10.1002/j.1875-9114.1985.tb03423.x. PMID 3906584. S2CID 25559476.
Centers for Disease Control Prevention (CDC) (December 2020). “Guidelines for Gonococcal Infection, 2020.”. 《MMWR. Morbidity and Mortality Weekly Report》 69 (50): 1911–1916. doi:10.15585/mmwr.mm6950a6. PMC 7745960. PMID 33332296.
Shiffman ML, Keith FB, Moore EW (December 1990). “Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility”. 《Gastroenterology》 99 (6): 1772–8. doi:10.1016/0016-5085(90)90486-K. PMID 2227290.
Shrimali JD, Patel HV, Gumber MR, Kute VB, Shah PR, Vanikar AV, Trivedi HL (November 2013). “Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation”. 《Indian Journal of Critical Care Medicine》 17 (6): 394–5. doi:10.4103/0972-5229.123465. PMC 3902580. PMID 24501497.
Guleria VS, Sharma N, Amitabh S, Nair V (Sep–Oct 2013). “Ceftriaxone-induced hemolysis”. 《Indian Journal of Pharmacology》 45 (5): 530–1. doi:10.4103/0253-7613.117758. PMC 3793531. PMID 24130395.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). “Ceftriaxone and acute renal failure in children”. 《Pediatrics》 133 (4): e917–22. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). “Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events”. 《Pediatrics》 123 (4): e609–13. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923.
van Heijenoort J (March 2001). “Formation of the glycan chains in the synthesis of bacterial peptidoglycan”. 《Glycobiology》 11 (3): 25R–36R. doi:10.1093/glycob/11.3.25r. PMID 11320055. S2CID 46066256.
Scheffers DJ, Pinho MG (December 2005). “Bacterial cell wall synthesis: new insights from localization studies”. 《Microbiology and Molecular Biology Reviews》 69 (4): 585–607. doi:10.1128/MMBR.69.4.585-607.2005. PMC 1306805. PMID 16339737.
Patel IH, Kaplan SA (October 1984). “Pharmacokinetic profile of ceftriaxone in man”. 《The American Journal of Medicine》 77 (4C): 17–25. PMID 6093513.
Nau R, Sörgel F, Eiffert H (October 2010). “Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections”. 《Clinical Microbiology Reviews》 23 (4): 858–83. doi:10.1128/CMR.00007-10. PMC 2952976. PMID 20930076.
Arvidsson A, Alván G, Angelin B, Borgå O, Nord CE (September 1982). “Ceftriaxone: renal and biliary excretion and effect on the colon microflora”. 《J Antimicrob Chemother》 10 (3): 207–15. doi:10.1093/jac/10.3.207. PMID 6292158.
Blumer J (September 1991). “Pharmacokinetics of ceftriaxone”. 《Hosp Pract (Off Ed)》. 26 Suppl 5: 7–13; discussion 52–4. doi:10.1080/21548331.1991.11707737. PMID 1918224.
Balant L, Dayer P, Auckenthaler R (1985년 4월 1일). “Clinical pharmacokinetics of the third generation cephalosporins”. 《Clinical Pharmacokinetics》 10 (2): 101–43. doi:10.2165/00003088-198510020-00001. PMID 3888488. S2CID 23478077.
Klein NC, Cunha BA (July 1995). “Third-generation cephalosporins”. 《Med Clin North Am》 79 (4): 705–19. doi:10.1016/s0025-7125(16)30034-7. PMID 7791418.

dailymed.nlm.nih.gov

“Ceftriaxone- ceftriaxone sodium injection, powder, for solution”. 《DailyMed》. 2019년 12월 31일. 2015년 11월 17일에 원본 문서에서 보존된 문서. 2020년 2월 1일에 확인함.
“DailyMed – Search Results for ceftriaxone”. 《dailymed.nlm.nih.gov》. 2016년 3월 6일에 원본 문서에서 보존된 문서. 2015년 11월 4일에 확인함.

semanticscholar.org

api.semanticscholar.org

Beam TR (1985). “Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life”. 《Pharmacotherapy》 5 (5): 237–53. doi:10.1002/j.1875-9114.1985.tb03423.x. PMID 3906584. S2CID 25559476.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). “Ceftriaxone and acute renal failure in children”. 《Pediatrics》 133 (4): e917–22. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). “Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events”. 《Pediatrics》 123 (4): e609–13. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923.
van Heijenoort J (March 2001). “Formation of the glycan chains in the synthesis of bacterial peptidoglycan”. 《Glycobiology》 11 (3): 25R–36R. doi:10.1093/glycob/11.3.25r. PMID 11320055. S2CID 46066256.
Balant L, Dayer P, Auckenthaler R (1985년 4월 1일). “Clinical pharmacokinetics of the third generation cephalosporins”. 《Clinical Pharmacokinetics》 10 (2): 101–43. doi:10.2165/00003088-198510020-00001. PMID 3888488. S2CID 23478077.

utah.edu

healthcare.utah.edu

“FDA Updates warning on Ceftriaxone-Calcium injection”. 2009년 11월 28일에 원본 문서에서 보존된 문서.

web.archive.org

“Ceftriaxone Sodium Monograph for Professionals”. Drugs.com. 2016년 5월 31일에 원본 문서에서 보존된 문서. 2016년 8월 27일에 확인함.
“Ceftriaxone- ceftriaxone sodium injection, powder, for solution”. 《DailyMed》. 2019년 12월 31일. 2015년 11월 17일에 원본 문서에서 보존된 문서. 2020년 2월 1일에 확인함.
“Rocephin Prescribing Information” (PDF). Roche. 2016년 3월 4일에 원본 문서 (PDF)에서 보존된 문서. 2015년 11월 1일에 확인함.
“The Use of Cephalosporins in Penicillin-allergic Patients”. 《www.medscape.com》. 2015년 11월 14일에 원본 문서에서 보존된 문서. 2015년 11월 10일에 확인함.
“FDA Updates warning on Ceftriaxone-Calcium injection”. 2009년 11월 28일에 원본 문서에서 보존된 문서.
“DailyMed – Search Results for ceftriaxone”. 《dailymed.nlm.nih.gov》. 2016년 3월 6일에 원본 문서에서 보존된 문서. 2015년 11월 4일에 확인함.
《Nursing Pharmacology Made Incredibly Easy!》. Lippincott Williams & Wilkins. 2012년 3월 7일. 496쪽. ISBN 9781451146240. 2016년 6월 3일에 원본 문서에서 보존된 문서.